Shouldn’t VIVUS Raise Capital Now? (VVUS)

February 23, 2012 · Filed Under Diabetes, fda, Financial, Heart, obesity, Secondary Offering 

While we have started mostly using The Wire at 247wallst.com for our biotech and active trader posts (among many other aspects 50 to 100 times per day), we have a question for BioHealthInvestor readers after VIVUS, Inc. (NASDAQ: VVUS) has basically doubled on news of Qnexa getting a recommendation for approval from a FDA panel…

If you were the CEO or CFO of VIVUS, wouldn’t you immediately go out and raise capital now?

Our take is not just “yes” but a resounding yes.  With $150 million or so in net tangible assets as of September 30, 2011, with a ten-year history, and for many more reasons, this would seem like a shoe-in for a capital raise.

FULL ANALYSIS HERE  

Set your RSS Readers and bookmarks to our Live Wire for continuous financial coverage.

Comments

8 Responses to “Shouldn’t VIVUS Raise Capital Now? (VVUS)”

  1. Neilesh on March 5th, 2012 12:01 am

    I came across your blog when googling for cool biotechnology articles – didn’t expect to find this, but enjoyed some of your posts. Keep it up.

  2. Technical Indicator on April 11th, 2012 12:20 pm

    Great work on the Biotech stock analysis Dr Melvin.

    I have enjoyed reading some of your posts and will come back for some more biotech insight soon.

    Thanks

  3. ft8rwfElite on September 10th, 2012 8:34 pm

    Automated High-Quality Multi-Level Link Building !
    http://biohealthinvestor.com/
    4uk4qg4mc4iy

  4. Superman Leather Jacket on November 28th, 2013 3:34 pm

    Superb write-up I like the write-up enjoy how we outlined as much as possible, what you are doing a fantastic task most of other people just like you through of which sort of informative blogs supply attention to help people related to lots of things. We study another fascinating weblogs out of your internet sites and I will be a lot serious together with your blogging and site-building knowledge, I additionally started to produce blogs and this form weblogs really guide me personally out there. We currently book marked your current page and distributed your web sites for you to my own fellow workers not only everyone yet every one of them just like the blogging and site-building knowledge, trust anyone write additional exciting websites such as this one particular along with enjoy for the foreseeable future blogs.

  5. Superman Leather Jacket on November 28th, 2013 3:35 pm

    Exceptional article I really like your current content love the way you outlined all things, you do an incredible employment many of other folks as if you through that will style of educational blogs offer attention to be able to us associated with many points. We study some other intriguing information sites through your web sites as well as We are a lot engaged along with your blogs expertise, My spouse and i additionally started to compose information sites this also sort information sites actually help myself out. I witout a doubt saved the webpage as well as discussed the sites in order to my own friends not just everyone yet them all just like the blogging abilities, trust an individual create a lot more fascinating websites this way one and all the best . on your upcoming sites.

  6. 逆向网赚 on October 24th, 2015 8:54 am

    逆向直销,震撼来袭:

    优势①:逆向网赚,真正实现就算什么不干都赚钱
    优势②:十级提成,下线年年续费,上线年年收钱
    优势③:静态分红,每日签到就有钱,封顶一百元
    优势④:百万资源,每日更新,一键转存无限下载
    优势⑤:强大网站,八个栏目,无限发布产品广告

    免费注册地址:

    http://www.629494567.9489988.com/

  7. Geen on October 28th, 2015 9:42 am

    精准医疗又叫个性化医疗,是指以个人基因组信息为基础,结合蛋白质组,代谢组等相关内环境信息,为病人量身设计出最佳治疗方案,以期达到治疗效果最大化和副作用最小化的一门定制医疗模式。因此相较传统医疗,精准医疗具有针对性、高效性及预防性等特征。

    美国医学界在2011年首次提出了“精准医学”的概念,今年1月20日,奥巴马又在美国国情咨文中提出“精准医学计划”,希望精准医学可以引领一个医学新时代。10月8日,2015全球创新论坛纽约峰会在纽约穆迪总部大楼举办。乐土投资集团CEO刘如银在峰会上介绍了他的精准医疗生态圈的想法。

    刘如银介绍了乐土投资在美国的国际化实践,包括在美国的地产投资拓展,以及最新投资的医疗健康项目。乐土投资集团(CLIG)定位以硅谷的高科技投资为引擎,以科技医疗和互联网金融为两翼,链接最具价值的深科技健康项目,服务国际大健康和科技发展。

    美国财政预算计划在2016年拨付给美国国立卫生研究院(NIH)、美国食品药品监督管理局(FDA)、美国国家医疗信息技术协调办公室(ONC)等机构共2.15亿美元用于资助这方面的科学研究与创新发展。

    刘如银说:美国的精准医疗主要是围绕着基因组、蛋白组等方面的检测,也就是围绕分子生物学的特性,针对个体化的病理特征进行治疗。而我们所关注的不仅如此,更是系统化的,全过程、全要素、全局性的对医疗过程和临床实践进行优化。我们所指的精准医疗也是针对每一个病人的具体病情,正确选择并精确的应用适当的治疗方法。刘如银认为:精准医疗的最终目标是以最小化的医源性损害、最低化的医疗资源耗费去获得最大化的病患的效益,其前景不可限量。

    精准医疗要做到个性、高效及预防的关键在于筛查和诊断,因此基因测序等检测诊断技术的发展是关键。成本的下降让基因测序商业化市场的打开成为可能,基因测序技术的成熟和商用经过了多年的发展,1980 年自动测序仪出现,2001 年完成了人类基因组框架图标志着这一技术的成熟,2007 年二代基因测序技术大幅降低测序成本,使得这一技术应用出现可能,以走在前列的Illumina 公司为例,该公司自2007 年起把当时每个基因组的测序成本费用从1000万美元降到了当下的1000 美元, 根据Illumina 公司数据,全球NGS(二代基因测序)的应用市场规模预计为200 亿美元,药品研发和临床应用是增速最快的领域,增速超过15%,肿瘤诊断和个性化用药是最有应用前景的领域,市场规模120亿美元。乐土投资与Illumina以及新一代的基因检测公司Genalyte, Centrillion都有着合作关系。

    刘如银说:精准医疗作为医疗模式的革新对提高我国国民健康水平有重要意义,将在基因测序技术发展和国家政策的推动下迎来黄金发展期。精准治疗是下一个新兴朝阳行业,我们关注基因测序、肿瘤诊断及个性化用药等相关投资机会。

    全球创新论坛纽约峰会由全美华人金融协会(The Chinese Finance Association, TCFA) 主办。全美华人金融协会于一九九四年在美国成立。分布在世界各地的会员来自华尔街投行、基金、监管部门、和学术界,已成为联系中美金融界最重要的桥梁之一。协会定期举行学术年会。协会本部设在纽约,并在波士顿,华盛顿,旧金山,伦敦,香港,北京和上海等金融中心设有分会。

    原招商银行行长马蔚华,中信银行美国分行行长文兵,汉世纪投资管理有限公司合伙人吴皓,联合国南南合作办首席经济与投资专家杨庆宏等参加了本年度会议并发表了讲话。

  8. 0969ku on December 13th, 2015 9:46 pm

    我来看看,欢迎不欢迎?

Leave a Reply




    Subscribe to BioHealth Investor BioHealth Investor RSS Feed